Cellectar Biosciences (CLRB) Return on Capital Employed (2011 - 2026)
Cellectar Biosciences (CLRB) posted Return on Capital Employed of 228.58% for Q4 2025, up 29.61% sequentially from 324.73% in Q3 2025, and up 682.0% YoY from 29.23% in Q4 2024.
Cellectar Biosciences (CLRB) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cellectar Biosciences has reported Return on Capital Employed for 15 years, with the latest figure at 228.58% in Q4 2025.
- Quarterly Return on Capital Employed rose 682.0% year-over-year to 228.58% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 228.58% (up 682.0% YoY) and the FY2025 annual result came in at 148.48%, up 40310.0% from the prior year.
- Return on Capital Employed grew to 228.58% in Q4 2025 per CLRB's latest filing, from 324.73% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 3990.4% in Q1 2024 and troughed at 469.95% in Q1 2023.
- A 5-year average of 126.86% and a median of 144.59% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 446035 bps in 2024, then slumped 430373 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 67.81% in 2021, then plunged by 375 bps to 321.83% in 2022, then jumped by 242 bps to 455.93% in 2023, then tumbled by 152 bps to 235.4% in 2024, then rose by 3 bps to 228.58% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 228.58%, 324.73%, and 427.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | -115.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -115.57% |
| Dec 31, 2025 | -228.58% |
| Sep 30, 2025 | -324.73% |
| Jun 30, 2025 | -427.80% |
| Mar 31, 2025 | -313.33% |
| Dec 31, 2024 | -235.40% |
| Sep 30, 2024 | -396.03% |
| Jun 30, 2024 | -227.22% |
| Mar 31, 2024 | 3,990.40% |
| Dec 31, 2023 | 455.93% |
| Sep 30, 2023 | 214.06% |
| Jun 30, 2023 | 1,395.33% |
| Mar 31, 2023 | -469.95% |
| Dec 31, 2022 | -321.83% |
| Sep 30, 2022 | -176.33% |
| Jun 30, 2022 | -112.85% |
| Mar 31, 2022 | -87.77% |
| Dec 31, 2021 | -67.81% |
| Sep 30, 2021 | -52.80% |
| Jun 30, 2021 | -41.97% |